Thermo Fisher's NSCLC Companion Dx Covered by Regence BCBS

Oct 16, 2017

UPDATE: The story had incorrectly stated that the test was FDA approved as a companion diagnostic to identify patients with ALK mutations who may respond to the cancer drug Xalkori. We regret the error.

NEW YORK (GenomeWeb) – Thermo Fisher Scientific today said its Oncomine Dx Target Test has received a positive coverage decision from Regence Blue Cross Blue Shield.

As a result, the insurer will cover the test for its members with non-small cell lung cancer in Oregon, Idaho, Utah, and certain counties in Washington.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

Featured White Papers

Discovering Neuronal Cell Types

Immuno-Oncology: 3 Strategies for Applying Humanized Models

A Guide to Selecting Your Next Immuno-Oncology Model

The Foundry Model is Coming to Molecular Diagnostics, Courtesy of the Semiconductor Industry

Jun

05

Featured Webinar

Text Mining at Sanofi for Genotype-Phenotype Associations in Multiple Sclerosis

This webinar will discuss how Sanofi used literature mining to annotate the association of human leukocyte antigen (HLA) alleles with diseases and drug hypersensitivity as part of a multiple sclerosis (MS) biomarker discovery project.

Jun

14

Featured Webinar

Overcoming Challenges in Hematological Genomic Testing with Advanced AI

This webinar will discuss an effort underway at the University of North Carolina Medical Center's to overcome limitations in the hematological genomic testing workflow with artificial intelligence (AI) from Sophia Genetics.

Jun

19

Featured Webinar

RNA in situ Hybridization: The Next Generation of Immunohistochemistry?

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

Jun

26

Featured Webinar

The Landscape of Alternative Polyadenylation in the Lung Cancer Transcriptome

This webinar outlines a study that sought to characterize the landscape of alternative polyadenylation (APA) in the lung cancer transcriptome in order to gain insight into the role of APA in cancer progression.

Main menu